Key facts
- Kexing Biopharm has dosed the first subject in China for its Phase I clinical trial of GB10.
- GB10 is an innovative ophthalmic drug developed by Shenzhen Kexing Pharmaceutical Co, Ltd.
- The trial is taking place in Shenzhen.
Shenzhen Kexing Pharmaceutical Co, Ltd. has recently dosed the first subject in China for its Phase I clinical trial of GB10, an innovative ophthalmic drug developed independently by the company. The trial is being conducted in Shenzhen.